OriginTrail and Oxford PharmaGenesis partner to build the world’s first decentralized, AI-ready clinical trial data network.
Author: Sahil Thakur
On September 2, 2025, OriginTrail and Oxford PharmaGenesis announced a strategic partnership to improve the way clinical trial data is managed and shared using a decentralized network . Their goal is to build the first decentralized and AI-ready pool of clinical knowledge. This effort targets long-standing problems in the pharmaceutical sector, including data fragmentation, limited access, and verification challenges.
OriginTrail brings its Decentralized Knowledge Graph (DKG) technology, which ensures tamper-proof and verifiable data. Oxford PharmaGenesis contributes its deep experience in scientific and medical communications. Together, they aim to support researchers, patients, and AI systems with trusted and accessible information.
Clinical trial data is currently spread across registries, regulatory filings, and journals. These sources often remain disconnected. As a result, it becomes difficult to verify information and draw reliable insights. This partnership directly addresses that issue.
OriginTrail will structure this data into “Knowledge Assets” published on the DKG. Each asset will include its original source and proof of authenticity. These assets will also connect to related information using cryptographic links. Researchers will benefit from faster evidence gathering. At the same time, AI systems will access structured, verified data instead of scraping unreliable web content.
Oxford PharmaGenesis will also help convert complex clinical results into plain-language summaries. These summaries will make the information easier for patients and healthcare professionals to understand.
To ensure the system supports next-generation AI, the team will enable decentralized retrieval-augmented generation (RAG). This will allow AI models to pull from verified clinical data, reducing risks of misinformation or hallucinated outputs.
The project will also introduce a pharmaceutical-specific “paranet,” a domain-focused subnet within the DKG. Pharma companies and other data providers can contribute to this network and earn $TRAC token rewards. Meanwhile, users and AI agents who access the data will use $TRAC to query the system. This setup creates strong incentives to grow the network while preserving data ownership.
The project will begin with a pilot using public data from a major pharmaceutical company. Although the partner is unnamed, it is likely one of Oxford PharmaGenesis’s top clients. This first step will demonstrate how data is published and linked in the DKG.
After the pilot, the team will invite other pharma leaders to contribute. Over time, the network is expected to include billions of data points. The goal is to build a global, constantly updated knowledge graph that supports better research, faster development, and broader transparency.
OriginTrail will manage the technical side, using its scalable Polkadot-based infrastructure. Oxford PharmaGenesis will continue validating and formatting the content to ensure quality and compliance.
This new OriginTrail clinical network could reduce research time by as much as 50 percent. It also has the potential to lower drug development costs and speed up regulatory approval timelines. For AI developers, the system provides a reliable data source, which reduces bias and improves accuracy.
The partnership builds on OriginTrail’s past work in pharma, such as its projects with BSI and the Sustainable Medicines Partnership. It also expands Oxford PharmaGenesis’s efforts to increase transparency in medical research.
Together, the two companies are laying the foundation for a decentralized, verifiable, and AI-compatible future in life sciences. As decentralized science (DeSci) gains momentum, this collaboration is likely to have a lasting impact on how clinical knowledge is created, shared, and used.
| Rank | Token | Symbol | Approx. Market Cap |
|---|---|---|---|
| 1 | Bio Protocol | BIO | $280–$290 million |
| 2 | OriginTrail | TRAC | $175–$185 million |
| 3 | ResearchCoin | RSC | $55–$60 million |
Our Crypto Talk is committed to unbiased, transparent, and true reporting to the best of our knowledge. This news article aims to provide accurate information in a timely manner. However, we advise the readers to verify facts independently and consult a professional before making any decisions based on the content since our sources could be wrong too. Check our Terms and conditions for more info.
